The short answer
Edwards Lifesciences is HALAL in ZakatInvest's qualitative classification, and its current asset-based financial ratios pass the examined methods. The company develops heart valves and critical-care technologies that generally support preservation of life. Product materials, clinical use, access and acquisition exposure still require continuing review.
This is a reproducible research screen, not a fatwa or investment recommendation. Apply the principles of your school and consult a qualified scholar for a binding ruling.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.
598.5 / 13,321.2
3,715.6 / 13,321.2
3,418.5 / 13,321.2
33.5 / 1,648.6
- Financial
- Pass
- Overall
- Incomplete
Debt is 4.49%, cash plus identifiable debt securities are 27.90%, receivables plus cash are 25.66% and disclosed net interest income is 2.03%; the examined financial ratios pass, while product materials and clinical-use questions remain qualitatively incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt is 4.49%, liquidity is 27.90% and receivables plus cash are 25.66%, below the examined MSCI total-assets limits. This is a calculation against the named method, not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt is 4.49% and liquidity is 27.90%, below the examined Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Edwards Lifesciences develops transcatheter and surgical heart valves, transcatheter mitral and tricuspid therapies and critical-care technologies. Medical devices that treat disease and preserve life are generally permissible, while animal-derived materials, clinical use and product-specific evidence require continuing review.
Limitation: The filing does not allocate revenue by biological material, procedure, clinical use or customer contract into a universal prohibited-revenue numerator; no blanket zero-concern claim is made.
Purification
Edwards discloses net interest income but does not prescribe a scholar-approved purification percentage. Readers should follow the qualified scholar or methodology they use rather than applying an invented fixed rate.
Inputs, assumptions and primary sources
- Inputs use Edwards Lifesciences' March 31, 2026 Form 10-Q; amounts are USD millions as presented in the filing.
- Debt uses the $598.5 million carrying value of the 4.3% senior notes; no revolving-credit balance was outstanding. Operating lease liabilities are not entered as conventional debt.
- Cash uses $2,445.5 million of cash and cash equivalents. Interest-bearing securities use $1,270.1 million of disclosed debt securities, including held-to-maturity bank time deposits and available-for-sale commercial paper, government and agency, asset-backed and corporate debt securities.
- Receivables use $775.7 million of accounts receivable plus $197.3 million of other receivables reported on the balance sheet.
- Quarterly net sales are $1,648.6 million and disclosed net interest income is $33.5 million. No fixed purification percentage is prescribed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Current quantitative screen
The calculations use Edwards Lifesciences' official filing at the SEC (Q1 2026 Form 10-Q). Amounts are in USD millions and use total assets as the denominator.
- Interest-bearing debt / assets: 4.49%, using the reported senior notes.
- Cash plus identifiable debt securities / assets: 27.90%, using cash and disclosed debt securities.
- Receivables plus cash / assets: 25.66%, using accounts receivable, other receivables and cash.
- Disclosed net interest income / revenue: 2.03% for the quarter. No universal purification percentage is prescribed.
The examined FTSE, MSCI and Malaysia total-assets financial ratios pass. Market-cap denominator methods are not calculated because ZakatInvest does not store a licensed, reproducible historical market-cap series.
What Edwards Lifesciences does
Edwards Lifesciences develops transcatheter aortic, mitral and tricuspid therapies, surgical heart valves and critical-care monitoring systems. Its first-quarter 2026 filing reports $1,648.6 million of net sales, with growth driven primarily by its valve therapies.
Medical technology that treats disease, reduces suffering and preserves life is generally permissible commerce and aligns with the maqasid principle of preservation of life. The filing does not allocate revenue by product material, procedure, clinical use or customer contract into a prohibited-revenue numerator, so the qualitative conclusion is transparent rather than an invented zero-concern percentage.
Debt, investments and mixed income
At March 31, 2026, Edwards reported $13,321.2 million of assets, $2,445.5 million of cash and cash equivalents, $1,270.1 million of debt securities, $973.0 million of receivables and $598.5 million of senior notes. The filing also reports investment activity and an acquisition that can change the company's financial profile.
Net interest income was $33.5 million for the quarter. We report the disclosed figure and its ratio for transparency, but Edwards does not prescribe a scholar-approved purification amount; readers should follow their qualified scholar or methodology rather than an old fixed estimate.
Qualitative considerations
- Animal-derived materials: some heart valves use bovine pericardial tissue. Necessity, transformation and product-specific treatment differ across scholars and should be reviewed with a qualified scholar.
- Clinical ethics: safety, informed consent, recalls, evidence, access and pricing remain relevant Islamic-ethics questions.
- Acquisitions: the Autus transaction, contingent consideration and investment impairments can change product mix, goodwill and financial exposure.
- Operations: manufacturing, regulatory, intellectual-property, labor and supply-chain obligations remain material diligence topics.
- Income treatment: investment and interest income are disclosed, but the filing does not select a universal purification rule.
The halal verdict
Edwards Lifesciences remains HALAL in ZakatInvest's qualitative classification, with the current examined financial ratios passing while product-material and purification questions remain methodology- and scholar-dependent. This is not an official index membership or fatwa. Revisit the record when Edwards files new statements or materially changes its debt, investments, products or biological-material disclosures.
Use the quantitative screen alongside your school's principles and consult a qualified scholar before investing.
Check another asset →